These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26907624)

  • 1. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
    Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
    J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
    Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
    Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
    Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
    J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes.
    Kinberger GA; Prakash TP; Yu J; Vasquez G; Low A; Chappell A; Schmidt K; Murray HM; Gaus H; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3690-3. PubMed ID: 27268307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid-phase synthesis of 5'-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry.
    Prakash TP; Brad Wan W; Low A; Yu J; Chappell AE; Gaus H; Kinberger GA; Østergaard ME; Migawa MT; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4127-30. PubMed ID: 26299345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides.
    Yamamoto T; Sawamura M; Wada F; Harada-Shiba M; Obika S
    Bioorg Med Chem; 2016 Jan; 24(1):26-32. PubMed ID: 26678173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Silencing Activity and Hepatic Accumulation of Antisense Oligonucleotides Bearing Cholesterol-Conjugated Thiono Triester at the Gap Region.
    Nakajima M; Kasuya T; Yokota S; Onishi R; Ikehara T; Kugimiya A; Watanabe A
    Nucleic Acid Ther; 2017 Aug; 27(4):232-237. PubMed ID: 28418770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice.
    Shimizu R; Kitade M; Kobayashi T; Hori S; Watanabe A
    J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):67-77. PubMed ID: 25376372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
    Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient Synthesis and Biological Evaluation of 5'-GalNAc Conjugated Antisense Oligonucleotides.
    Østergaard ME; Yu J; Kinberger GA; Wan WB; Migawa MT; Vasquez G; Schmidt K; Gaus HJ; Murray HM; Low A; Swayze EE; Prakash TP; Seth PP
    Bioconjug Chem; 2015 Aug; 26(8):1451-5. PubMed ID: 26011654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes.
    Prakash TP; Yu J; Migawa MT; Kinberger GA; Wan WB; Østergaard ME; Carty RL; Vasquez G; Low A; Chappell A; Schmidt K; Aghajan M; Crosby J; Murray HM; Booten SL; Hsiao J; Soriano A; Machemer T; Cauntay P; Burel SA; Murray SF; Gaus H; Graham MJ; Swayze EE; Seth PP
    J Med Chem; 2016 Mar; 59(6):2718-33. PubMed ID: 26914862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.
    Tanowitz M; Hettrick L; Revenko A; Kinberger GA; Prakash TP; Seth PP
    Nucleic Acids Res; 2017 Dec; 45(21):12388-12400. PubMed ID: 29069408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers.
    Subramanian RR; Wysk MA; Ogilvie KM; Bhat A; Kuang B; Rockel TD; Weber M; Uhlmann E; Krieg AM
    Nucleic Acids Res; 2015 Oct; 43(19):9123-32. PubMed ID: 26446989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor.
    Schmidt K; Prakash TP; Donner AJ; Kinberger GA; Gaus HJ; Low A; Østergaard ME; Bell M; Swayze EE; Seth PP
    Nucleic Acids Res; 2017 Mar; 45(5):2294-2306. PubMed ID: 28158620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface Plasmon Resonance Assay of Binding Properties of Antisense Oligonucleotides to Serum Albumins and Lipoproteins.
    Onishi R; Watanabe A; Nakajima M; Sekiguchi M; Kugimiya A; Kinouchi H; Nihashi Y; Kamimori H
    Anal Sci; 2015; 31(12):1255-60. PubMed ID: 26656814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
    Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
    Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
    Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
    Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of 5'-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies.
    Cedillo I; Chreng D; Engle E; Chen L; McPherson AK; Rodriguez AA
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28809818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Tolerability of GalNAc
    Baker BF; Xia S; Partridge W; Engelhardt JA; Tsimikas S; Crooke ST; Bhanot S; Geary RS
    Nucleic Acid Ther; 2024 Feb; 34(1):18-25. PubMed ID: 38227794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
    Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
    Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.